Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Thomas Velling

Diagnostic Radiology Newport Beach, CA Medical Doctor

NPI 1689618209 CMS profile 211649

One Hoag Drive, Newport Beach, CA 92663

Open in the dashboard

General payments

$9,035

144 records reported · program years 2019–2025

Research payments

$1,015

Paid to them · 2 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Thomas Velling of Newport Beach, CA is reported in the CMS Open Payments database as having received $9,035 across 144 general payments and $1,015 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $928 16
2024 General $445 13
2023 General $1,196 25
2022 General $1,258 30
2021 General $899 23
2020 General $3,454 18
2019 General $854 19
2019 Research $1,015 2

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Thomas Velling
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Thomas Velling were reported at $928. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Thomas Velling Diagnostic Radiology median Middle half National median
2019 $854 $108 $29–$318 $163
2020 $3,454 $65 $21–$252 $114
2021 $899 $92 $24–$292 $132
2022 $1,258 $104 $29–$294 $149
2023 $1,196 $110 $29–$337 $160
2024 $445 $113 $30–$356 $164
2025 $928 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. MicroVention, Inc. $2,994 9 payments
  2. Boston Scientific Corporation $1,150 18 payments
  3. Inari Medical, Inc. $788 8 payments
  4. Stryker Corporation $665 17 payments
  5. Medtronic, Inc. $614 22 payments
  6. Sirtex Medical Inc $494 4 payments
  7. Penumbra, Inc. $330 3 payments
  8. Bard Peripheral Vascular, Inc. $237 5 payments
  9. Surefire Medical, Inc. $233 6 payments
  10. Cardiva Medical, Inc. $211 9 payments
  11. Other $1,318 43 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $6,122 141 payments
  2. Consulting Fee $2,800 2 payments
  3. Travel and Lodging $113 1 payment
Products named General payments · program years 2019–2025
  1. SIR-Spheres Microspheres $494 4 payments
  2. FLOWTRIEVER CATHETER, S $476 7 payments
  3. ClotTriever $453 3 payments
  4. FlowTriever $453 3 payments
  5. Ruby $290 2 payments
  6. EMBOLD Fibered $282 2 payments
  7. CT THROMBECTOMY SYSTEM KIT $276 5 payments
  8. TRINAV INFUSION SYSTEM $233 6 payments
  9. General - IO Ablation $219 2 payments
  10. Indigo $208 2 payments
  11. Other $3,852 125 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. MicroVention, Inc. $1,015 2 payments

Prescribing to Medicare patients

Part D · data year 2024 · 2 drugs

Part D claims

39

Median for Diagnostic Radiology: 24

Drug cost

$137

Median for Diagnostic Radiology: $190

Branded share of claims

0%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Methylprednisolone Generic 19 $92
Ciprofloxacin Hcl Generic 20 $44

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 187 billing codes

Paid by Medicare

$135,338

Medicare's payments for the services billed

Medicare patients

1,522

Average age 77

Services billed

2,679

809 women, 713 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 61%
Ischemic heart disease 37%
Atrial fibrillation 32%
Chronic kidney disease 32%
Diabetes 31%
Heart failure 27%
Cancer 27%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

146 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record